301239 Chengdu Bright Eye Hospital
- 51.53
- -0.02-0.04%
Chengdu Bright Eye Hospital News
Express News | Sinqi Eye Medicine: Aier Eye Hospital Group and others have reached a cooperation with the company and will introduce low-concentration atropine in the near future
Puri Ophthalmology (301239): Under pressure from 23 years of high performance growth base, 24Q1 performance is under pressure
Core view: Puri Ophthalmology released 23 and 24Q1 results. In '23, the company achieved revenue of 2,718 billion yuan (+57.50%); net profit to mother of 268 million yuan (+1202.56%); deducted not to mother
Dongwu Securities released a research report on April 25 stating that it gave Puri Ophthalmology (301239.SZ) a purchase rating. The main reasons for the rating include: 1) Cataract achieved rapid growth in 2023, and gross margins of various businesses inc
Dongwu Securities released a research report on April 25 stating that it gave Puri Ophthalmology (301239.SZ) a purchase rating. The main reasons for the rating include: 1) Cataract achieved rapid growth in 2023, and gross margins of various businesses increased simultaneously; 2) the non-profit margin of all businesses increased significantly in 2023, and all expense ratios declined; 3) 2024Q1 revenue increased slightly and profits declined. It is expected that the reason is that the cataract business continues to grow and the refractive optometry business is under pressure. (Mainichi Keizai Shimbun)
A-share changes丨Q1 performance was under pressure, and Puri Ophthalmology once fell more than 11% to a record low
Glonghui, April 24 | Puri Ophthalmology (301239.SZ) once fell by more than 11%. The low was 45.23 yuan, a new low since listing, and its total market capitalization fell below 7 billion yuan. According to news, the company's main revenue for the first quarter was 676 million yuan, up 4.01% year on year; net profit to mother was 16.924,900 yuan, down 89.58% year on year. The company's net profit returned to mother last year was 268 million yuan, an increase of 1202.56% over the previous year. It can be seen from this that the company's performance in the first quarter of this year was clearly under pressure.
The medical services sector opened and fell, and Puri Ophthalmology fell by more than 10%
The medical services sector opened and declined. As of press release, Puri Ophthalmology and Jinkai Biotech had fallen by more than 10%, while Hongbo Pharmaceutical and Huaxia Ophthalmology had followed suit.
Express News | Puri Ophthalmology: Net profit due to mother in 2023 was 268 million yuan, an increase of 1202.56% year-on-year
Express News | Puri Ophthalmology: Adhere to medical properties and build long-term value
Express News | Midday announcement: Funeng Oriental extends the validity period of the 2023 shareholders' meeting resolution to issue shares to specific targets
Puri Ophthalmology (301239.SZ): A total cost of 59.77 million yuan to buy back 0.5% of shares
Gelonghui, March 1 | Puri Ophthalmology (301239.SZ) announced that as of March 1, 2024, the total number of shares repurchased by the company through centralized bidding transactions through a special securities repurchase account was 755,267 shares, accounting for 0.50% of the company's total share capital. The highest transaction price was 102.00 yuan/share, the minimum transaction price was 54.94 yuan/share, and the transaction amount was 59,770,175.60 yuan (excluding transaction fees). At this point, the company's actual repurchase amount has reached the lower limit of the total repurchase capital in the repurchase plan, and has not exceeded the maximum limit of the total repurchase capital. The actual repurchase period is 2
Express News | 228 companies' annual results are expected to increase
Express News | 269 listed companies released performance forecasts: nearly 80% are happy, 72 companies are expected to increase by more than 100%
Express News | 67 GEM companies announced their 2023 performance forecasts, and Puri Ophthalmology expects net profit growth of 1224.75% to lead the way
Express News | Puri Ophthalmology: Net profit is expected to be 260 million yuan to 285 million yuan in 2023, an increase of 1163.98%-1285.51%; the company's overall performance resumed rapid growth. In particular, the medical demand accumulated in the previous year was
Puri Ophthalmology (301239.SZ): A total cost of 299.753 million yuan to buy back 313,800 shares
Gelonghui, January 2, 丨 Puri Ophthalmology (301239.SZ) announced that as of December 31, 2023, the total number of shares repurchased by the company through centralized bidding transactions through special securities accounts was 313,800 shares, accounting for 0.21% of the company's total share capital. The highest transaction price was 102.00 yuan/share, the minimum transaction price was 87.47 yuan/share, and the transaction amount was 29.9753 million yuan (excluding transaction fees).
Puri Ophthalmology (301239): A rising star in the ophthalmology industry continues to expand from the bottom up
Recommended logic: 1) The company has set up 27 ophthalmology specialist hospitals and 3 ophthalmology clinics, covering municipalities directly under the Central Government and major provincial capitals across the country. It is expected that 2024 will continue to expand, and the new hospital will continue to inject vitality into the company's performance growth; 2) The company's business
Puri Ophthalmology (301239.SZ): The first repurchase of 40,000 shares on November 27 involved a capital of 3,7481 million yuan
Gelonghui November 28 | Puri Ophthalmology (301239.SZ) announced that on November 27, 2023, for the first time, the company repurchased the company's shares through a centralized bidding transaction through a special securities repurchase account. The number of shares repurchased this time was 40,000 shares, accounting for 0.03% of the company's total share capital. The highest transaction price was 95.75 yuan/share, the lowest transaction price was 92.72 yuan/share, and the transaction amount was 3,7480.77 million yuan (excluding transaction fees).
Puri Ophthalmology (301239): Performance is in line with expectations and is steadily advancing the “national chain+city integration” layout strategy
Event Overview The company achieved revenue of 2.166 billion yuan (yoy +51.2%) in 23Q1-Q3; net profit of 317 million yuan (yoy +237.5%); net profit of 317 million yuan (yoy +237.5%); net profit of 230 million yuan (yo)
Puri Ophthalmology (301239): Maintaining rapid growth in performance and continuing to build a highland of talents
Core point of view: Puri Ophthalmology released its 2023 three-quarter report. The company achieved operating income of 2.116 billion yuan in the first three quarters of 2023, +51.19% year-on-year; net profit to mother was 317 million yuan, +237.48 million yuan year-on-year
Puri Ophthalmology (301239) 2023 Third Quarter Report Review: Maintaining High Growth in the Third Quarter, Repurchasing Shares Shows Confidence in Long-term Development
Matters: The company released its three-quarter report for 2023. Revenue for the first three quarters was 2.166 billion yuan (+51.2%), net profit was 317 million yuan (+237.5%), and net profit after deducting non-net profit was 230 million yuan (+1)
Puri Ophthalmology (301239.SZ) released the first three quarter results, net profit of 317 million yuan, an increase of 237.48%
Puri Ophthalmology (301239.SZ) released its report for the third quarter of 2023. The company's revenue for the first three quarters was 2...
Analysis
Price Target
No Data
